Dr. Lal Path Labs Ltd.

NSE: LALPATHLAB · Healthcare

₹1,970.00+0.16%06 Nov 2026

Ask the data

Instant answers about Dr. Lal Path Labs Ltd. — computed from its filings, no language model

Market cap₹33,057 cr

Current price₹1,970.00

High / Low₹2,029 / ₹1,308

P/E56.7

P/B12.04

Book value₹163.6

ROE21.3%

ROCE29.2%

Debt / equity0.00

Dividend yield0.67%

EPS (TTM)₹34.77

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	1,057	1,203	1,330	1,581	2,087	2,017	2,227	2,461	2,763
EBITDA	264	294	344	436	561	490	609	696	782
Operating margin	25.0%	24.4%	25.8%	27.6%	26.9%	24.3%	27.4%	28.3%	28.3%
Interest	1	1	15	16	30	38	29	22	23
Depreciation	33	38	73	77	108	150	144	142	162
Profit before tax	261	301	310	394	475	344	506	625	669
Tax	90	100	83	98	125	103	143	132	159
Net profit	171	199	226	292	345	239	358	487	505
EPS ₹	20.85	24.19	27.42	35.33	41.70	28.82	43.05	58.48	30.24
Operating cash flow	—	—	—	—	447	456	535	569	636
Capex	—	—	—	—	476	45	58	54	173
Dividend paid	—	—	—	—	117	103	201	207	223
Total assets	916	1,090	1,374	1,661	2,353	2,386	2,456	2,717	3,146
Equity	788	946	1,033	1,245	1,508	1,666	1,849	2,173	2,508

Quarterly performance

last 34 quarters · ₹ crore

showing latest 8 of 34 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	267	292	318	292	301	335	366	328	302	266	432	452	431	607	498	486	503	534	489	491	541	601	539	545	602	660	597	603	670	731	660	703	798	874
Operating profit	64	75	87	66	66	95	109	82	57	48	127	139	122	189	142	121	118	144	113	116	146	178	141	145	170	202	154	169	192	224	179	187	248	280
Operating margin	24.0%	25.7%	27.3%	22.4%	22.0%	28.4%	29.8%	25.1%	19.0%	18.2%	29.5%	30.7%	28.3%	31.2%	28.4%	24.9%	23.4%	26.9%	23.1%	23.5%	27.0%	29.6%	26.1%	26.5%	28.2%	30.7%	25.8%	28.0%	28.7%	30.7%	27.2%	26.6%	31.0%	32.1%
Other income	9	9	11	12	14	14	15	14	12	11	13	14	14	14	14	12	8	9	10	14	14	18	18	18	21	22	25	26	28	25	24	24	32	34
Interest	0	0	0	0	0	4	4	4	4	4	4	4	4	5	5	12	8	11	9	9	8	8	7	7	6	6	5	5	5	5	7	6	6	7
Depreciation	11	9	9	10	10	16	18	19	20	18	20	20	20	19	20	38	36	39	38	38	35	36	36	37	35	35	36	36	35	40	42	45	44	47
Profit before tax	62	75	88	68	69	89	102	73	45	38	117	129	111	179	131	84	81	103	76	83	118	152	116	120	150	183	138	153	181	204	124	160	229	261
Tax	22	26	31	22	22	30	21	18	13	10	30	33	26	46	34	21	23	30	23	26	34	42	34	34	42	52	40	-2	47	51	33	28	58	67
Net profit	40	49	57	46	47	59	80	54	32	28	85	94	83	131	95	61	58	72	53	57	83	109	81	84	106	129	97	155	132	151	90	131	170	192
EPS ₹	4.88	6.00	6.92	5.56	5.72	7.14	9.77	6.56	3.94	3.45	10.34	11.44	10.10	15.87	11.49	7.41	6.97	8.64	6.37	6.84	9.95	13.16	9.77	10.13	12.79	15.52	11.60	18.57	15.88	18.05	5.42	7.86	10.15	11.51
Revenue YoY	—	—	—	—	12.9%	14.7%	15.1%	12.1%	0.2%	-20.6%	18.1%	38.0%	42.9%	128.0%	15.4%	12.6%	-17.1%	7.1%	—	1.1%	7.6%	12.6%	10.1%	11.1%	11.3%	9.8%	10.7%	10.5%	11.3%	10.7%	10.6%	16.6%	19.1%	19.6%
Profit YoY	—	—	—	—	17.5%	19.0%	41.2%	18.1%	-31.0%	-51.7%	6.0%	74.7%	156.6%	362.0%	11.4%	-26.5%	-56.0%	-24.5%	—	-7.5%	43.2%	52.4%	54.0%	49.0%	28.8%	18.2%	18.9%	83.2%	24.4%	16.6%	-6.4%	-15.2%	28.0%	27.6%

Earlier results (standalone, Dec '15 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Dr. Lal Path Labs Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY17†
Revenue	882
Operating profit	229
Operating margin	26.0%
Other income	26
Depreciation	32
Profit before tax	223
Tax	76
Net profit	147

Quarters

showing latest 8 of 9 periods

	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	182	191	216	253	200	213	242	269	254
Operating profit	69	52	58	77	46	48	64	75	54
Operating margin	37.7%	27.4%	27.0%	30.6%	22.8%	22.4%	26.3%	27.8%	21.4%
Other income	5	6	6	8	7	6	8	8	7
Interest	0	0	0	—	0	0	0	0	0
Depreciation	8	8	7	8	8	9	6	7	8
Profit before tax	82	50	57	77	44	45	65	75	54
Tax	22	18	19	26	15	16	22	25	19
Net profit	60	32	38	51	29	29	43	50	35
EPS ₹	7.26	3.93	4.54	6.21	3.51	3.52	5.30	6.15	4.28
Revenue YoY	—	—	—	—	9.9%	11.5%	12.1%	6.5%	27.2%
Profit YoY	—	—	—	—	-51.6%	-10.0%	14.8%	-2.4%	20.6%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 28 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	24.4%	21.1%	22.1%	24.6%	25.4%	21.9%	18.9%	19.4%	23.3%	23.4%	31.7%	32.5%	15.7%	14.3%	15.8%	17.0%	18.6%	19.3%	20.6%	20.1%	20.8%	22.4%	23.6%	22.4%	22.1%	20.1%	21.6%	21.3%
ROCE	37.4%	31.9%	33.7%	35.6%	36.6%	31.5%	26.6%	28.0%	33.4%	33.0%	44.4%	45.6%	21.5%	20.0%	21.9%	24.4%	26.4%	27.7%	29.3%	29.1%	30.1%	29.8%	31.2%	29.2%	28.6%	27.6%	29.5%	29.2%
Net margin	16.4%	16.6%	16.7%	17.9%	18.1%	17.0%	15.5%	15.1%	16.6%	18.4%	20.5%	20.3%	12.1%	11.8%	12.8%	14.2%	15.2%	16.1%	16.7%	17.1%	17.3%	19.8%	20.3%	20.6%	19.8%	18.3%	18.7%	19.2%
EBITDA margin	24.9%	24.4%	25.2%	25.9%	26.5%	25.8%	23.5%	23.7%	25.6%	27.6%	30.0%	29.7%	24.6%	24.3%	25.2%	26.0%	26.7%	27.4%	27.7%	28.0%	27.9%	28.3%	28.4%	28.4%	28.7%	28.3%	29.0%	29.5%
Debt / equity	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.15	0.14	0.14	0.07	0.07	0.05	0.05	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	327.00	376.75	72.50	42.62	30.07	21.29	18.05	18.65	22.23	25.65	32.69	32.23	9.52	10.17	11.27	13.67	15.74	18.19	20.63	23.22	25.74	29.01	32.23	35.16	31.53	30.35	30.37	30.09
Asset turnover	1.28	1.10	1.14	1.19	1.22	0.97	0.92	0.97	1.06	0.95	1.16	1.20	0.87	0.85	0.86	0.87	0.89	0.91	0.93	0.90	0.93	0.91	0.93	0.88	0.90	0.88	0.92	0.88

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 14 periods

	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	83	83	83	83	83	83	83	84	84	84	84	84	168	168
Other equity / reserves	705	862	949	1,162	1,425	1,466	1,583	1,689	1,766	1,918	2,089	2,304	2,341	2,577
Total equity	788	946	1,033	1,245	1,508	1,550	1,666	1,772	1,849	2,002	2,173	2,388	2,508	2,744
Borrowings	—	—	0	0	346	237	237	125	83	42	0	0	0	0
Current liabilities	116	138	227	274	500	450	470	471	465	462	402	433	451	488
Non-current liabilities	8	1	93	111	310	269	216	168	105	100	108	104	154	190
Total assets	916	1,090	1,374	1,661	2,353	2,302	2,386	2,445	2,456	2,598	2,717	2,959	3,146	3,458
Property, plant & equipment	160	160	157	158	205	416	401	347	343	328	336	429	484	521
Capital work-in-progress	10	3	10	6	14	7	3	10	4	1	4	17	6	5
Investments	145	185	164	59	65	124	150	110	114	289	327	486	423	530
Inventories	27	29	57	43	53	54	34	41	37	47	36	50	44	56
Receivables	41	53	51	67	85	92	71	86	77	90	88	101	111	141
Cash & equivalents	66	129	197	244	378	51	264	120	361	107	293	116	243	344

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 9 periods

	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	197	219	284	398	447	456	535	569	636
Cash from investing	-172	-100	-26	-212	-449	-287	-24	-303	-422
Cash from financing	13	-55	-190	-139	136	-283	-414	-334	-264
Capex	72	42	80	60	476	45	58	54	173
Free cash flow	125	176	204	339	-29	411	478	515	462
Dividends paid	32	55	156	99	117	103	201	207	223

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹521 cr15%

CWIP

₹5 cr0%

Investments

₹530 cr15%

Inventories

₹56 cr2%

Receivables

₹141 cr4%

Cash & equivalents

₹344 cr10%

Other assets

₹1,860 cr54%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Dr. Lal Path Labs Ltd.	33,057	1,970.00	56.7	12.04	21.3%

StoxGud checklist: Bullish setup · 9/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+1.3%

6 months+25.8%

1 year+27.5%

3Y CAGR+14.2%

5Y CAGR+1.5%

10Y CAGR+12.9%

50-day avg₹1,920.28

200-day avg₹1,650.80

RSI (14)65

Compare Dr. Lal Path Labs Ltd. with

Aster DM Quality Care vs Dr. Lal Path Labs Dr. Lal Path Labs vs Piramal Pharma Dr. Lal Path Labs vs Wockhardt Dr. Lal Path Labs vs Acutaas Chemicals Dr. Lal Path Labs vs Krishna Institute of Medical Sciences

FAQs

What is the share price of Dr. Lal Path Labs Ltd.?

Dr. Lal Path Labs Ltd. (LALPATHLAB) closed at ₹1,970.00 on NSE on 06 Nov 2026.

What is the market cap of Dr. Lal Path Labs Ltd.?

₹33,057 crore at the latest close.

What is the P/E ratio of Dr. Lal Path Labs Ltd.?

56.7, on trailing-twelve-month earnings from its filings.

How fast is Dr. Lal Path Labs Ltd. growing?

Dr. Lal Path Labs Ltd.: revenue has compounded at 11.1% a year over three years; net profit at 28.3% a year. Latest-quarter revenue is up 19.6% year on year, profit up 27.6%.

How profitable is Dr. Lal Path Labs Ltd.?

On a trailing-twelve-month basis return on equity is 21.3%, return on capital employed 29.2%, operating margin 29.5%, net margin 19.2%.

How much debt does Dr. Lal Path Labs Ltd. have?

Dr. Lal Path Labs Ltd. is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹344 cr (balance sheet of 2026-09-30). Operating profit covers interest 30.1 times.

Financials parsed from Dr. Lal Path Labs Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '18. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.